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Background: As HIV infection continues to devastate low-income countries, efforts to search for an effective
HIV vaccine are crucial. Therefore, participation in HIV vaccine trials will be useful for the development of a
preventive vaccine that will work and thus reduce the global HIV epidemic.
Objective: The objective of this study was to analyse the willingness to volunteer (WTV) in a Phase I/II HIV
vaccine trial among police officers in Dar es Salaam, Tanzania.
Design: We included a convenience sample of 329 participants (79% males) from sensitisation workshops that
were held once at each of the 32 police stations. Participants were recruited from 23 stations which were
included according to availability. Data about personal characteristics, general HIVand AIDS knowledge and
sexual behaviour, attitudes towards vaccines and willingness to participate in the HIV vaccine trial were
obtained through an interview-administered questionnaire with both closed and open-ended questions.
Results: Overall, 61% of the participants expressed WTV in HIV vaccine trials. WTV was significantly
associated with: positive attitude towards use of effective vaccine, Odds ratio (OR), 36.48 (95% CI: 15.07
88.28); the intention to tell others about one’s decision to participate in the trial, OR, 6.61 (95% CI: 3.89
11.24); Tanzania becoming a partner in developing the vaccine, OR, 4.28 (95% CI: 2.288.03); having an extra
sexual partner, OR, 3.05 (95% CI: 1.635.69); perceived higher risk of getting HIV infection, OR, 2.11 (95%
CI: 1.343.33); and high knowledge about HIV and AIDS, OR, 1.92 (95% CI: 1.223.01).
Conclusion: The results indicated that a majority of police officers in this study were willing to participate in
HIV vaccine trials. However, there is a need to provide the respondents with precise information about the
purpose of a Phase I/II HIV vaccine trial and the fact that it does not protect against HIV infection, in order
to avoid increasing risky behaviour.
Keywords: HIV vaccine trials; willingness; police ofﬁcers; Tanzania
Received: 12 February 2009; Revised: 17 June 2009; Accepted: 9 July 2009; Published: 7 August 2009.
I
n common with many other sub-Saharan countries,
Tanzania is facing challenges in controlling HIV
transmission, highlighting the inadequacy of current
HIV prevention efforts in Africa (1). The HIV and AIDS
epidemic in Tanzania appears to be relatively stable at
6.2% in the population segment aged 1549 years old (2).
The epidemic shows strong regional variations (3, 4) and
urban residents have considerably higher infection levels
at 10.9% compared with rural residents 5.2% (5). In
Tanzania, the primary mechanism for HIV transmission
is unprotected heterosexual intercourse, and the most
important factor that fuels the HIV epidemic is unpro-
tected sex with multiple concurrent partners (6). The
current national response is directed towards increasing
individual and community awareness of the risk of
HIV and its serious implications for the individual, the
family and the community (4). Anti-retroviral therapy is
currently available, but only 20% of all adults and
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DOI: 10.3402/gha.v2i0.1953children with advanced HIV infection are able to access it
(7). Despite all these efforts, new infections continue to
occur due to sexual practices with concurrent sexual
partners without protection (611).
The availability of a safe, effective and accessible
preventive vaccine may represent a long-term hope for
controlling the HIV pandemic, especially in low-income
countries (12). Development of an HIV vaccine is
difficult. With the existing different HIV subtypes, multi-
ple trials are needed from different geographical sites. A
large number of HIV vaccine trials have been done in
United States (US) and Europe but only a few in low-
income countries, where the HIV infection rates and the
burden of disease is the highest in the world (13).
However, injectable drug users, gay and bisexual men,
men who have sex with men and women vary greatly in
their willingness to participate in vaccine trials according
to a systematic review of HIV vaccine preparedness
studies in the Organization for Economic Co-operation
and Development (OECD) countries (14). Results from
such contexts may not be generalised to countries such as
Tanzania where those at risk are generally people aged
1549 years old, and the major HIV transmission route is
heterosexual contact (6).
Tanzania is one of the low-income countries that has
met WHO eligibility criteria for conducting Phase I/II
HIV vaccine trials. Although the main focus of a Phase I/
II HIV vaccine trial is to evaluate the safety and
immunogenic effect of the vaccine (13), understanding
the potential participants’ willingness to take part in the
trial is crucial for the development of future vaccines. In
earlier studies, willingness to take part in HIV vaccine
trials was associated with the perception of one’s own risk
of getting HIV infection (1518) and the desire to help
the community (15, 19, 20). In the Ugandan military,
willingness to take part in the HIV vaccine trial was
associated with sexual risk-taking and unrealistic expec-
tations of the vaccine’s capacity to protect against
infection (21). Very little is known about willingness to
participate in the Tanzanian context. In the present study,
we describe willingness and associated factors to join in a
Phase I/II HIV vaccine trial among members of the
police force in Dar es Salaam, Tanzania.
Methods
This study is part of a larger HIV and AIDS study in
Tanzania that includes studies of HIV incidence; studies
of laboratory reference values as well as willingness to
participate in an HIV vaccine trial, leading up to a
subsequent vaccine trial in the police cohort. Thus, the
police force is a cohort with data collection at different
stages. This study was carried out in 23 out of 32 police
stations, which were purposively included according to
availability of the study participants. The 32 stations serve
both urban and peri-urban areas of Dar es Salaam region
and they are scattered in the three municipalities: Temeke,
Kinondoni and Ilala. About 3,000 police officers, of
whom 20% are women, make up the police force in Dar es
Salaam. In the present study, 21% were female. Police
officers were chosen for the study because they are well
educated in the sense that the majority have attained four
years of secondary education, come from an established
organisation and are easy to access. A previous study had
proven that they could make independent informed
decisions to take part in HIV incidence studies which
had gained the support of higher police authorities (22).
Between August 2005 and November 2006, we re-
cruited a sample of 594 police officers through sensitisa-
tion workshops to assess the existing socio-behavioural
attitudes in preparation of the Phase I/II HIV vaccine
trial. These workshops were held in the selected police
stations, and all the staff were invited. The workshops
were organised by a field team (doctors, nurses and
counsellors from Muhimbili University and national
referral hospital together with collaborators from the
police force, a medical doctor and a nurse from
the Health Unit in the police force) to update the police
officers with basic information about HIV infection at
national and individual level. The workshops were
designed to inform the police officers about the nature
of the HIV incidence study and the HIV vaccine trial
project. An information booklet describing the study
more in detail was made available to participating police
officers in the national language, Kiswahili. Thus, all
participants received general information about the
nature of the project, what was expected of the partici-
pating officers, potential benefits, impact on the police
force at large, study duration and study objectives.
Forty-six visits were made for data collection, i.e. two
visits within each of the selected stations. During the first
visit, written consent was only obtained from those who
were interested to participate in the studies after the
workshop. Respondents’ characteristics were recorded
in the enrolment document. A pre-tested, interviewer-
administered questionnaire with both closed and
open-ended questions (first questionnaire) regarding
knowledge, attitudes about HIV and AIDS and sexual
practices was given. Pre-test counselling was provided
before HIV testing. During the second visit, seven days
later, post-test counselling and HIV results were given
and a second written consent was obtained before filling
out the questionnaire (second questionnaire) on vaccine
knowledge, attitudes to vaccine studies and willingness,
which was administered regardless of the HIV status of
the participant. All questions were posed in the national
language. Trained counsellors and researchers completed
the questionnaires. During both contacts, participants
were encouraged to ask for clarifications on any issue
concerning the study individually. Questionnaires were
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(page number not for citation purpose)double-checked by two people the next day, before entry
into the database.
One hundred and five interviewees (17.7%) did not
complete a second questionnaire. The main reason was
that respondents did not come for HIV test results at the
second study visit where the second questionnaire was
completed. Of these 105, 13 (12%) came but did not want
to complete the second questionnaire after testing HIV
positive. The counsellors adhered strictly to rules of
confidentiality during the second visit by only providing
the first author (EAMT) with the total number of
individuals declining and the reasons for not completing
the questionnaire. Also, during the second visit, 160
(26.9%) of respondents bypassed the first questionnaire,
allegedly because of time constraints. They requested just
taking the HIV test. The two questionnaires were finally
combined using proxies of the individuals’ unique
identities to associate the selected variables. Thus, we
enrolled a convenience sample of 329 (55.39%) police
officers who completed both questionnaires (Fig. 1).
Data analysis
Data analysis was carried out in three stages.
The frequency distribution of all variables was tabu-
lated. Four statements assessed HIV and AIDS knowl-
edge where each correct response scored 1 and each
incorrect one scored 0, the median score being 4. Sixteen
statements assessed attitudes towards condom use, each
positive response scoring 1 and each negative one scoring
0, while the median score was 12. Scores for HIV and
AIDS knowledge were dichotomised as ‘high knowledge’
for those who scored above or on a par with the median
(median score]4) or ‘low knowledge’ (median scoreB
4). Scores for attitudes towards condom use were
dichotomised as ‘positive attitude towards condom use’
(median score 12) or ‘negative attitude towards condom
use’ (median score512). Knowledge about how avaccine
works was assessed by asking an open-ended question
analysed as either ‘Right’, ‘Not right’ or ‘I do not know’.
‘Right’ means a vaccine protects one from infection and
‘Not right’ means otherwise. Attitudes towards vaccines
were assessed by using ‘Yes’ or ‘No’ or ‘I don’t know’
responses. The respondents were given the opportunity to
justify the ‘Yes’ and ‘No’ choices. The open-ended
questions gave multiple responses but we report the
percentage for the main identified reason only.
We analysed the willingness and examined the associa-
tion between willingness and socio-demographic charac-
teristics, knowledge, attitudes, self-perception of risk and
risk behaviours. The willingness to volunteer (WTV) for
the HIV vaccine trial was assessed by ‘Yes’ and ‘No’
choices. Cross tabulation was performed between all
variables.
Binary logistic regression was performed to estimate
the Odds ratio (OR) and 95% CIs of factors associated
with WTV for the HIV vaccine trial. Missing responses
were not analysed and non-significant results are not
reported. Statistical analysis was conducted using SPSS
15.0 for Windows (SPSS, Inc Chicago, IL, USA).
Ethical issues
The project was reviewed and approved by the Institu-
tional Review Board at Muhimbili University of Health
and Allied Sciences (MUHAS), formally Muhimbili
University College of Health Sciences (MUCHS). Each
police officer provided written consent after reading and
allegedly understanding all the details about the study.
The police higher authority was informed about the study
both orally and in writing. They received a written
information sheet followed by a check list before com-
mencement of the study to ensure their understanding of
the principal study concepts.
Results
Socio-demographic and behavioural characteristics
of the study population
The median age of the 329 participants interviewed was
37 years (range 1961 years) and 79% were male. Whereas
females dominated in the youngest age group,524 years,
there was a majority of males in the oldest age group,
45 years. A higher proportion of males and females
were married (68%) and single (62%), respectively. Most
were Christians, educated to four years in secondary
school with a median of three children. Females were less
likely to have had four or more lifetime partners. Condom
594 police officers investigated
in incidence study 
160 (26.94%)
did not
complete first
questionnaire
105 (17.68%)
did not
complete
 second
questionnaire
329
(55.39%)
Completed both first and
 second  questionnaire.That
is in addition they tested for
HIV and took the HIV test
results as well
Fig. 1. Study population
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extra-marital sexual encounters, whereas 60% considered
themselves at risk (Table 1).
Knowledge about vaccines and experiences
Almost all (95% of 260 males and 90% of 69 females)
knew in principle how vaccines work, that they protect
from infections, and had also been vaccinated at some
time (95% males and 94% females). However, a majority
(70% males and 55% females) were not able to recall their
vaccination experiences.
Attitudes to HIV vaccines
Use of an effective HIV vaccine
Most respondents (79% of 260 males and 71% of 69
females) would use an effective vaccine against HIV, if it
Table 1. Socio-demographic and behavioural characteristics of the participants
Sex
Response Male (column%) Female (column%) Total (column%)
Age distribution
Up to 24 years 34 (13.1) 20 (29.0) 54 (16.4)
2534 years 70 (26.9) 18 (26.1) 88 (26.7)
3544 years 87 (33.5) 22 (31.9) 109 (33.1)
45 years 69 (26.5) 9 (13.0) 78 (23.7)
Marital status
Married 176 (68.0) 26 (37.7) 202 (61.6)
Single
a 83 (32.0) 43 (62.3) 126 (38.4)
Religion
Christian 174 (66.9) 46 (66.7) 220 (69.9)
Muslim 86 (33.1) 23 (33.3) 109 (33.1)
Education
Primary 102 (39.4) 31 (44.9) 133 (40.5)
Secondary and above 157 (60.6) 38 (55.1) 195 (59.5)
Number of children
None 82 (31.5) 28 (40.6) 110 (33.4)
One or more 178 (68.5) 41 (59.4) 219 (66.6)
Has additional sexual partner
b
Yes 80 (57.6%) 23 (60.5) 103 (58.2)
No 59 (42.4) 15 (39.5) 74 (41.8)
Lifetime sexual partners
13 105 (58.3) 40 (93.0) 145 (65.0)
Four or more 75 (41.7) 3 (7.0) 78 (35.0)
Attitude towards condom use
Positive 135 (55.1) 34 (51.5) 169 (54.3)
Negative 110 (44.9) 32 (48.5) 142 (45.7)
Condom use with additional partner
c
Yes 109 (55.3) 22 (47.8) 131 (53.9)
No or don’t know 88 (44.7) 24 (52.2) 112 (46.1)
Likelihood of getting infected
Not possible or don’t know 107 (41.3) 23 (33.8) 130 (39.8)
Possible 152 (58.7) 45 (66.2) 197 (60.2)
aNot married/divorced/separated/widowed.
bDo you have a regular sexual partner, someone else other than wife/husband?
cWhen you last had sex with someone other than wife or husband, did you use a condom?
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the fear of vaccine side effects. Six percentage were not
sure.
Tanzania becoming a partner in developing an HIV
vaccine
Almost all (85% of 259 males and 78% of 69 females) said
‘Yes’ to the question: ‘Do you think that Tanzania should
be a partner in developing HIV vaccine that is especially
designed for Tanzania?’ In responses to the open-ended
question, the most commonly stated reason was that
involving Tanzania would reassure them about the safety
of the vaccine. Of those who said no (11%), the main
reason was lack of trust in vaccine trials (e.g. Why should
this vaccine be special for Tanzanians only?). Five
percentage were not sure.
Sharing the intention to participate with significant others
(sexual partner, parents, friends and relatives)
Most (69% of 236 males and 54% of 63 females)
responded ‘Yes’ to the question: ‘If you were to partici-
pate in a HIV vaccine trial, would you tell anyone? If yes,
whom would you tell?’ The most common person to
share the information with would be the sexual partner
and the most commonly reason stated for sharing was to
take care of them if they suffered from side effects of the
vaccine. The unmarried/divorced/separated/widowed sta-
ted that they would share the information with friends,
family members, relatives or parents in that order.
Similarly, the most common reason stated was to be
taken care of if one was adversely affected by the vaccine.
For those who felt no reason to tell anyone (15%), they
said that the main reason was that participation would be
a personal decision. Nineteen percentage were undecided.
Willingness to volunteer (WTV) for an HIV vaccine trial
Sixty-one percentage (64% of the 260 males and 54% of
the 69 females) would volunteer for an early vaccine trial
(Phase I or II) that is designed to determine its safety. The
most commonly stated reason was altruism, i.e. to save
the nation. Thirty-nine percentage were not ready to
volunteer because of the fear of vaccine side effects.
Factors associated with willingness to volunteer
(WTV) for the HIV vaccine trial
The associations were examined between WTVand socio-
demographic variables, knowledge of HIV and AIDS,
attitudes towards the use of the effective vaccine, risk-
related variables and perceived risks in a multivariate
logistic regression model (Table 2). WTV was positively
associated with: positive attitude towards using an
effective HIV vaccine if available (OR, 36.48; 95% CI:
15.0788.28); Tanzania becoming a partner in develop-
ment of HIV vaccine (OR, 4.28; 95% CI: 2.288.03) and
the intention to tell others about one’s decision to
participate in the trial (OR, 6.61; 95% CI: 3.8911.24).
Other factors were having a regular sexual partner other
than one’s wife or husband (OR, 3.05; 95% CI: 1.63
5.69); perceived risk of getting infected with HIV (OR,
2.11; 95% CI: 1.343.33) and high knowledge about HIV
and AIDS (OR, 1.92; 95% CI: 1.223.01).
Discussion
Overall, our data illustrated that police officers would be
willing to take part in an HIV vaccine trial and that
willingness was more positively associated with an inten-
tion to use than with an intention not to use an effective
vaccine, if one were made available. This may explain the
burden that HIV infection has imposed on people’s lives,
Table 2. Factors associated with willingness to volunteer
(WTV) in HIV vaccine trial in a multivariate analysis
WTV (Row%)
Variable Yes No Odds ratio (95% CI)
Would use effective HIV vaccine
a
Yes 196 (76.6)*** 60 (23.4) 36.48 (15.0788.28)
No or don’t
know
6 (8.2) 67 (91.8) 1
Tanzania as vaccine partner
b
Yes 184 (66.9)*** 91 (33.1) 4.28 (2.288.03)
No or don’t
know
17 (32.1) 36 (67.9) 1
Would you tell anyone?
c
Yes 157 (79.7)*** 40 (20.3) 6.61 (3.8911.24)
No or don’t
know
38 (37.3) 64 (62.7) 1
Has additional sexual partner
d
Yes 72 (69.9)*** 31 (30.1) 3.05 (1.635.69)
No 32 (43.2) 42 (56.8) 1
Likelihood of being infected
e
Possible 135 (68.5)** 62 (31.5) 2.11 (1.343.33)
Not possible or I
don’t know
66 (50.8) 64 (49.2) 1
Knowledge about HIV and AIDS
High 117 (68.8)** 53 (31.2) 1.92 (1.223.01)
Low 84 (53.5) 73 (46.5) 1
Significance marked as: **PB0.01; ***PB0.001.
aIf there was an effective vaccine against HIV, would you use it?
bDo you think Tanzania should be a partner in developing HIV
vaccines?
cIf you were to participate in a HIV vaccine trial, would you tell
anyone?
dDo you have a regular sex partner, someone else other than
wife/husband?
eWhat is the likelihood that you can be infected with HIV?
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of a study in the US among homosexual men, African
American women and persons who abuse substances, the
intent to be vaccinated if a FDA-approved vaccine
became available was low, only 30 and 25.3% were
extremely likely and likely, respectively, to accept such a
vaccine (23). In addition, the higher willingness asso-
ciated with Tanzania becoming a partner in the develop-
ment of a vaccine that is particularly designed for
Tanzania, is encouraging and provides a promising basis
for police officers possibly volunteering for the HIV
vaccine trials.
The increased willingness was associated with having
additional sexual partners, apart from a wife or husband.
Such risky behaviour is unsurprising, both among police
officers (22), and in a Tanzanian context. Previous studies
from Tanzania have documented the increase of HIV
transmission among those with multiple concurrent
partners (6, 8, 10, 11). Consequently, the increased
willingness to participate in the vaccine trial may be
associated with higher risky behaviour identified among
some respondents. Respondents might have been willing
to volunteer for personal protection against HIV infec-
tion as reported elsewhere (20, 21, 23, 24). The high
interest among police officers for taking part in a vaccine
trial might also have been influenced by unrealistic
expectations of continuing to have multiple sexual
partners as noted among the Ugandan military men
(21). In our study, over half of the respondents considered
themselves at risk. Our findings are supported by other
studies (1618) where willingness was influenced by
perceived self-risk for HIV infection.
The influence of sexual partners/spouses was impor-
tant in this study. The majority (66%) intended to share
their intention to take part in the HIV vaccine trial with a
‘significant other’, mainly the steady sexual partner. The
most common reason given was to have somebody who
would take care of them in case they experienced adverse
effects of the vaccine. Evidently, the possibility of an
adverse event associated with a vaccine is recognised, but
would not deter police officers from volunteering for the
trial. The greater willingness noted among those who
would tell others implies that significant others have an
important role in influencing volunteers to participate in
the HIV vaccine trial. In the previous studies, significant
others were found to be a potential source of stigma
towards those who would participate in HIV vaccine trial
(2529). Therefore, the role of the support of these
significant others should be recognised in the recruitment
and retention of volunteers.
The limitation of our data is based on methodological
challenges such as the recruited sample. Although police
officers are well organised, well educated and informed in
terms of HIV and AIDS-related issues, it was challenging
to engage them in responding to a long questionnaire,
due to unexpected emergency duties. The nature of the
group, however, facilitated access and follow up. They
were recruited to the study on the basis of specific health-
related information delivered during the meetings. Those
who participated in the meetings may have been particu-
larly interested in health-related matters. Therefore, we
can only generalise our results to the studied participants
and not to other populations.
The use of an interview-administered questionnaire
might have caused some hesitation in terms of responding
to sensitive questions about sexual practices. For in-
stance, fewer females responded to questions concerning
risk-related variables as compared to males. Some people
might find it sensitive to reveal the number of lifetime
sexual partners in a face-to-face interview. The counsel-
lors who were filling out the questionnaires reported that,
in many cases, the respondents just kept quiet when asked
that question, and sometimes requested the interviewer to
move on to another question. The interviewers of course
respected the respondents’ suggestions. Thus, there might
have been a higher frequency of risky behaviour than was
reported. The first author (EAMT) participated in the
sensitisation workshops and filling out the first ques-
tionnaire where she also noted hesitation among a few
participants in disclosing the number of sexual partners.
Conclusion
Our results add valuable information in relation to
interventions preceding HIV vaccine trials in low-income
countries such as Tanzania. The information is useful for
HIV vaccine development and hence contributes to the
global fight against HIV/AIDS. The fact that willingness
to participate in HIV vaccine trials among police officers
is highly associated with risky behaviour indicates a need
for an educational package on HIV prevention and
counselling, as well as risk behaviour screening among
those who volunteer for the trial. It is important to ensure
that the participants clearly understand the fact that the
trial does not offer protection from HIV transmission.
The expressed willingness and underlying concerns need
to be explored further, and here an explorative study may
be important in order to reveal hidden concerns.
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